SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare trades higher on the BSE

07 Dec 2020 Evaluate

Cadila Healthcare is currently trading at Rs. 477.35, up by 6.35 points or 1.35% from its previous closing of Rs. 471.00 on the BSE.

The scrip opened at Rs. 473.80 and has touched a high and low of Rs. 480.70 and Rs. 466.75 respectively.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 480.70 on 07-Nov-2020 and a 52 week low of Rs. 212.70 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 480.70 and Rs. 437.95 respectively.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 16.88% and 8.05% respectively.

Zydus Cadila has received permission to initiate the Phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate. NLRP3 inflammasomes are involved in the inflammation process by production and release of proinflammatory cytokines IL-1β and IL-18. This harmful inflammation within the body leads to the onset and development of various kinds of diseases, including Acute Respiratory Distress Syndrome (ARDS), auto-immune diseases, inflammatory diseases, cardiovascular diseases, metabolic disorders, Gastro-intestinal diseases (inflammatory bowel disease), renal diseases and CNS diseases.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×